NCT04994795Active, not recruiting
Predictive Multimodal Signatures Associated With Response to Treatment and Prognosis of Patients With Stage IV Non-small Cell Lung Cancer
Deep Learning-Enabled Exploration of Predictive Signatures in a Multicenter Retrospective and Prospective Observational Study Allowing the Analysis of the Aggregation of Multimodal Clinical, Biological, Genomic and Radiomics Data Associated With the Response to Treatment and Prognosis of Patients With Stage IV Non-small Cell Lung Cancer
Source: ClinicalTrials.gov · Last updated 21 Nov 2024
Brief summary (registry, in English)
Predicting response to therapy and disease progression in stage IV NSCLC patients treated with pembrolizumab monotherapy, chemotherapy-pembrolizumab combination therapy or chemotherapy alone in the first-line setting.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 4000 (estimated)
- First submitted
- 15 Jul 2021
- Start date
- Aug 2021
- Primary completion date
- Dec 2024
- Lead sponsor
- Sophia Genetics SAS
- Diseases
- Lung cancer
- NCT number
- NCT04994795
What you commit to
- Study type: Observational
- Planned participants: 4000
- From Aug 2021 to the primary completion date, Dec 2024
- 30 sites in 8 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior anti-cancer therapy for actual stage IV NSCLC
Other
- Critical data missing (e.g., PD-L1 status, baseline millimetric imaging, first evaluation millimetric imaging)
- Patients participating in other clinical trials that modify the standard of care
Who the study is looking for
- Adult ≥18 years old
- Patient diagnosed with Stage IV NSCLC (de novo or earlier stage progression to stage IV)
- Absence of oncogene activating mutations eligible patients to targeted therapy (EGFR, ALK)
- Cohort A: Received first line treatment with pembrolizumab monotherapy
- Cohort B: Received first line treatment with chemotherapy and pembrolizumab combination therapy
- Cohort C: Received first line treatment with chemotherapy doublet
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (30)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| DASA - Hospital Brasilia Coordinator of this site? Confirm its status | Brasília | Brazil | Unknown status |
| DASA - Hospital de Niteroi Coordinator of this site? Confirm its status | Niterói | Brazil | Unknown status |
| DASA - Hospital São Lucas Coordinator of this site? Confirm its status | Rio de Janeiro | Brazil | Unknown status |
| AC Camargo Coordinator of this site? Confirm its status | São Paulo | Brazil | Unknown status |
| DASA - Hospital Nove De Julho Coordinator of this site? Confirm its status | São Paulo | Brazil | Unknown status |
| Sunnybrook Health Sciences Centre Toronto Coordinator of this site? Confirm its status | Toronto | Canada | Unknown status |
| University Hospital Leipzig Coordinator of this site? Confirm its status | Leipzig | Germany | Unknown status |
| Puerta De Hierro Hospital Coordinator of this site? Confirm its status | Madrid | Spain | Unknown status |
| Fundación Jiménez Díaz Coordinator of this site? Confirm its status | Madrid | Spain | Unknown status |
| Instituto Valenciano de Oncologia Coordinator of this site? Confirm its status | Valencia | Spain | Unknown status |
| Avicenne Hospital Coordinator of this site? Confirm its status | Bobigny | France | Unknown status |
| CHU Bordeaux Coordinator of this site? Confirm its status | Bordeaux | France | Unknown status |
| Ambroise Paré Hospital Coordinator of this site? Confirm its status | Boulogne-Billancourt | France | Unknown status |
| Hospices Civils de Lyon Coordinator of this site? Confirm its status | Lyon | France | Unknown status |
| CHU de Nantes Coordinator of this site? Confirm its status | Nantes | France | Unknown status |
| La Pitié Salpêtrière Coordinator of this site? Confirm its status | Paris | France | Unknown status |
| Tenon Hospital Coordinator of this site? Confirm its status | Paris | France | Unknown status |
| Foch Hospital Coordinator of this site? Confirm its status | Suresnes | France | Unknown status |
| Centre Hospitalier de Toulon Coordinator of this site? Confirm its status | Toulon | France | Unknown status |
| Shaare Zadek Medical Center Coordinator of this site? Confirm its status | Jerusalem | Israel | Unknown status |
| Sourasky Medical Center Coordinator of this site? Confirm its status | Tel Aviv | Israel | Unknown status |
| University Hospital Of Parma Coordinator of this site? Confirm its status | Parma | Italy | Unknown status |
| Policlinico Gemelli Coordinator of this site? Confirm its status | Roma | Italy | Unknown status |
| Azienda Sanitaria Universitaria Friuli Centrale (ASU FC) Coordinator of this site? Confirm its status | Udine | Italy | Unknown status |
| Roswell Park Comprehensive Cancer Center Coordinator of this site? Confirm its status | Buffalo | United States | Unknown status |
| Holden Comprehensive Cancer Center at University of Iowa Health Care Coordinator of this site? Confirm its status | Iowa City | United States | Unknown status |
| Carbone Comprehensive Cancer Center at University of Wisconsin Coordinator of this site? Confirm its status | Madison | United States | Unknown status |
| Mayo Clinic Coordinator of this site? Confirm its status | Rochester | United States | Unknown status |
| Huntsman Cancer Institute Coordinator of this site? Confirm its status | Salt Lake City | United States | Unknown status |
| UMASS Memorial Health Coordinator of this site? Confirm its status | Worcester | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.